Apollon Wealth Management’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
Other funds holding DGX
AIM
EB
CPC
AIM
AAMU
AAIS
BCAM
Apollon Wealth Management's DGX Position: Q2 2026 in Review
Apollon Wealth Management reduced its Quest Diagnostics (DGX) stake by 0.47% in Q2 2026, selling an estimated $6.08K and leaving 6,572 shares worth $1.39M. The position accounts for 0.02% of the portfolio, ranked #608.
Apollon Wealth Management first reported a position in DGX in Q2 2022 and has held it in 17 quarters since. 287 funds tracked by Wall St. Rank hold DGX as of Q2 2026.
- Apollon Wealth Management held 6,572 shares of Quest Diagnostics worth $1.39M as of Q2 2026.
- Apollon Wealth Management sold 31 Quest Diagnostics shares in Q2 2026, an estimated $6.08K.
- Quest Diagnostics made up 0.02% of Apollon Wealth Management's portfolio in Q2 2026, its #608 holding.
- Apollon Wealth Management first reported a position in Quest Diagnostics in Q2 2022 and has held it in 17 quarters since.
- 287 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.
Based on Apollon Wealth Management's 13F filing for Q2 2026, filed 23 Jul 2026.